Enjoy complimentary customisation on priority with our Enterprise License!
The global drug discovery informatics market size is forecast to increase by USD 7.28 billion at a CAGR of 18.17% between 2023 and 2028. Market growth is spurred by various factors, the intricate and protracted drug discovery process involves several stages, including identification and synthesis of candidates, characterization, screening, and assays to assess therapeutic efficacy. Key steps, such as hit identification, hit-to-lead selection, lead optimization, and preclinical testing, contribute significantly to the process's time-consuming and costly nature. Drug development necessitates additional chemical steps, raw material sourcing and testing, analytical documentation, and stability testing, further increasing expenses.
The involvement of expert labor in pharmaceutical research significantly increases costs, leading pharmaceutical companies to outsource drug discovery activities to contract research organizations (CROs) and research institutes. CROs perform various drug discovery functions, such as library screening for potential drug candidates, optimizing small-scale purification methods, identifying metabolites, validating analytical techniques, managing clinical trials, and utilizing advanced technologies like preclinical isolated organ perfusion systems. These systems enable researchers to study the pharmacological effects of drugs on living organs, providing valuable data for drug development. The labor-intensive and costly data processing and interpretation from multiple instruments necessitate the adoption of sophisticated analytical software tools by drug manufacturers to boost productivity, accuracy, and effectiveness. The growing demand for CROs to deliver efficient drug discovery services with high accuracy in reduced time is projected to fuel the expansion of the global drug discovery informatics market.
To learn more about this report, Download Report Sample
In the realm of precision medicine, the drug discovery informatics market plays a pivotal role in enhancing medical care by facilitating the effectiveness of treatments for various patient groups. This market is driven by technological advancements in genetic and molecular profiling, which are essential for identifying novel medications and optimizing traditional procedures in the biotechnology industry. The drug discovery process involves the identification and validation of lead compounds, with a focus on early-stage research across diverse target classes.
Get a glance at the market contribution of various segments Download PDF Sample
The discovery informatics segment was valued at USD 1.39 billion in 2018. Technological tools such as high-throughput screening, molecular modeling, medicinal chemistry, and structural biology are employed to generate vast amounts of data, including gene sequencing and nucleic acid analysis. Data storage and collection are crucial components of the drug discovery informatics market, enabling the efficient organization and analysis of large datasets. Informatics software, such as sequence analysis platforms and bioinformatic solutions, are employed for data gathering, visualization, and processing.
In the realm of drug discovery and development, artificial intelligence (AI) informatics plays a pivotal role in transforming healthcare infrastructure. Leveraging AI algorithms, this market facilitates the analysis of intricate proteins, genome sequencing data, genes, and molecular modeling to unearth novel therapeutic compounds. Hit discovery and hit-to-lead optimization are expedited through data mining and advanced analytics technologies, enabling precision medicines and treatments for various diseases. The integration of AI in drug discovery informatics significantly reduces the timeline and enhances the agility of the drug discovery process. It offers increased accuracy in predicting the safety and efficacy of drugs, thereby contributing to the development of diversified drug pipelines for chronic diseases.
Moreover, the medical scientists and academics benefit from these informatics solutions by gaining access to extensive datasets and specialized expertise, which in turn fuels financial investments in research infrastructure and hardware. Moreover, AI-driven drug discovery workflows employ computational methods to target discovery sequencing and bioinformatics solutions, enabling the exploration of large datasets and biomolecular sequences. These advancements are expected to revolutionize the drug development landscape, ultimately leading to the creation of innovative treatments tailored to patient demographics and specific diseases.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 29% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period. Drug Discovery Informatics is a critical domain in the healthcare sector, leveraging advanced technologies to identify novel therapeutic compounds for various diseases. Proteins, genome sequencing data, and genes form the foundation of this market, with molecular modeling and hit discovery playing pivotal roles in the process. Hit-to-lead optimization ensures the transformation of hits into potential drug candidates, while healthcare infrastructure and drug development necessitate the integration of data mining and analytics technologies.
Moreover, precision medicines and treatments are increasingly reliant on Drug Discovery Informatics, as they require a deep understanding of patient demographics and medical scientists' expertise. Large datasets, systems, and specialized expertise are essential for computational drug discovery, which employs AI algorithms and informatics solutions to streamline workflows. Financial investments in research infrastructure and hardware further fuel the growth of this market. The Drug Discovery Informatics landscape encompasses target discovery sequencing, bioinformatics solutions, and biomolecular sequences, all aimed at advancing our knowledge of diseases and developing effective treatments. Chronic diseases, in particular, stand to benefit significantly from the insights gained through this market. By harnessing the power of data and advanced technologies, Drug Discovery Informatics is revolutionizing the way we approach healthcare and drug development.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Certara Inc.: The company offer drug discovery informatics such as Phoenix PK PD and Pinnacle 21.
Aragen Life Sciences Pvt. Ltd., Charles River Laboratories International Inc., ChemAxon Ltd., ChemBridge Corp., Collaborative Drug Discovery Inc., Cresset BioMolecular Discovery Ltd., Curia Global Inc., Dassault Systemes SE, Eurofins Scientific SE, Evotec SE, Infosys Ltd., Insilico Medicine, International Business Machines Corp., Jubilant Pharmova Ltd., Melissa Inc., OpenEye Scientific Software Inc., PerkinElmer Inc., Schrodinger Inc., Selvita SA, and Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The Drug Discovery Informatics Market is experiencing significant growth due to advancements in precision medicine and medical care. Effective patient groups are being formed based on genetic and molecular profiling, requiring large-scale data storage and collection. Technological advancements in gene sequencing, novel medications, and traditional procedure development are driving the need for informatics software in the biotechnology industry. Orphan drug research for rare diseases is also contributing to the market expansion. Sequence analysis platforms and bioinformatic solutions are essential tools for processing genome sequencing data, analyzing genes, and modeling drug molecules. Clinical trial design relies on data gathering and visualization to optimize outcomes. Nucleic acids, proteins, and genome sequencing data are integral components of this market.
The significance of precision medicine is a key driver shaping the market. Pharmaceutical and biopharmaceutical companies are investing substantially in Research and Development (R&D) activities to expand their product pipelines, particularly in therapeutic areas such as immunology, cancer, and infectious diseases. Advancements in technology, including gene sequencing, molecular profiling, and high-performance computing, have revolutionized the drug discovery process. Informatics software plays a pivotal role in data gathering, storage, and visualization, enabling researchers to analyze genetic and molecular data to identify novel medications and design clinical trials. The biotechnology industry's shift towards precision medicine and personalized treatments necessitates the use of informatics software for data analysis and interpretation. This is especially crucial for patient groups with rare diseases and those requiring orphan drug research. Cloud-based technology and cloud computing have become essential infrastructural technologies for drug discovery informatics, providing ample storage, processing power, and accessibility for scientific research.
Moreover, next-generation sequencing, Web services, and in-silico modeling tools are some of the key technologies utilized in drug discovery and development. The healthcare IT industries have embraced innovative pharmaceuticals and SARS-COV-2 vaccines, which have been developed using advanced informatics software and technologies. These advancements have led to significant progress in the treatment of infectious diseases and cancer diseases, among others. The drug discovery process involves sequence analysis platforms, bioinformatic solutions, and the manipulation of nucleic acids to develop drug molecules. The integration of these technologies with informatics software has streamlined the drug discovery process, making it more efficient and cost-effective. In conclusion, the drug discovery informatics market is a critical component of the biotechnology industry, driving the development of precision medicines and effective treatments for various chronic diseases. The integration of technological advancements, data gathering, data visualization, and informatics software has revolutionized the drug discovery process, enabling the development of novel medications and the design of clinical trials for infectious diseases, cancer diseases, and other therapeutic areas. Such factors will increase the market growth during the forecast period.
Pharmaceutical and biotech companies, as well as research institutes leveraging informatics software to optimize the drug discovery process is a new trend shaping the growth. The focus is on developing effective treatments for various chronic conditions and infectious diseases, including rare diseases and orphan drug research. Genetic and molecular profiling are integral to this process, with technological advancements in gene sequencing and next-generation sequencing playing a pivotal role. The biotechnology industry is harnessing the power of informatics software to store, collect, and process vast amounts of data generated from scientific research. This data is crucial for clinical trial design and sequence analysis platforms, enabling the development of novel medications and the validation of traditional procedures. In the context of SARS-COV-2 vaccines, cloud-based technology and cloud computing have facilitated the rapid storage, processing, and sharing of data.
Moreover, healthcare IT industries and innovative pharmaceuticals are investing in high-performance computing, web services, and in-silico modeling tools to analyze drug molecules and nucleic acids. These solutions offer significant advantages in terms of data gathering, data visualization, and price efficiency compared to traditional methods. In the fight against infectious diseases like cancer, informatics software is revolutionizing the drug discovery process, enabling the development of next-generation sequencing and High-performance computing tools. Bioinformatic solutions are essential for clinical trial design and the analysis of complex data sets. They offer significant advantages in terms of data storage, processing, and analysis, enabling researchers to gain valuable insights into the effectiveness of new medications and treatments. The integration of informatics software into the drug discovery process is a game-changer, offering significant potential for reducing costs, increasing efficiency, and improving the overall quality of medical care. Such factors will increase the market growth during the forecast period.
The high investments required for the Drug Discovery Informatics is a key challenge impeding growth. This sector facilitates the integration and aggregation of extensive data from various sources, enabling more effective treatments for patient groups. Genetic and molecular profiling are crucial components of this process, with technological advancements in gene sequencing and next-generation sequencing leading to the discovery of novel medications. Informatics software is essential for data gathering, storage, and visualization in drug discovery. These tools are instrumental in scientific research, from target identification to clinical trial design. The healthcare IT industries have embraced informatics software to optimize traditional procedures, leading to more efficient and cost-effective drug development. The biopharmaceutical sector's focus on rare diseases and orphan drug research necessitates the use of advanced informatics solutions. High-performance computing, web services, and in-silico modeling tools are employed to analyze nucleic acids and drug molecules, accelerating the development of innovative pharmaceuticals.
However, the cloud-based technology and cloud computing have revolutionized drug discovery informatics, offering enhanced storage, processing, and accessibility. This is particularly relevant in the context of SARS-COV-2 vaccines and other infectious diseases, where rapid data analysis is crucial. The drug discovery process is expensive, with costs ranging between USD800 million and USD2,000 million. Informatics software price is a significant consideration, but the potential benefits in terms of effectiveness and scientific research outweigh the costs. In summary, drug discovery informatics is a vital component of the biotechnology industry, driving advancements in precision medicine, medical care, and scientific research. It facilitates data collection, storage, and analysis, enabling the development of novel medications for various diseases, including cancer and infectious diseases. The use of informatics software, high-performance computing, and cloud-based technology is essential for accelerating the drug development process and reducing costs. Such factors will hinder the market growth during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The market is experiencing rapid growth due to various factors, such as precision medicine, which aims to tailor medical care to individual patients, increasing the effectiveness of treatments. Advances in genetic profiling and molecular profiling have paved the way for more targeted therapies, supported by continuous technological advancements in the field. The utilization of data storage and collection techniques, coupled with gene sequencing technologies, has enabled the discovery of novel medications. Genetic or molecular profiling has revolutionized healthcare, demanding robust data management, processing, and analysis. Compared to traditional procedures, research spending in rare diseases, including cancer, has surged, aided by next-generation sequencing in chemical laboratories and pharma nanotechnology sectors. Sequencing analysis, driven by bioinformatics tools, deciphers nucleic acid and protein biomolecular sequences, aiding in pregnancy, lactation, and COVID-19 drug discovery. Virtual screening techniques tackle SARS-CoV-2, enriching the pharmaceutical sector with data-driven software for drug design, preclinical research, and drug target identification. Machine learning tools enhance prediction of drug resistance and side effects, augmenting data science and analytics beyond conventional methods.
Moreover, the biotechnology industry is focusing on rare diseases and orphan drug research, leveraging informatics software for efficient data gathering and visualization. Collaborations between the Healthcare IT sector and pharmaceutical companies have led to the development of innovative pharmaceuticals, including SARS-COV-2 vaccines, utilizing cloud-based technology and computational resources for primary and secondary databases, scientific research, and drug discovery. Moreover, high-performance computing and Web services are facilitating clinical trial design and Sequence analysis platforms for hit discovery and hit-to-lead optimization. The market witnesses significant contributions from AI algorithms and artificial intelligence in bioinformatics solutions across middle and small-scale firms, accelerating drug discovery processes. Major pharmaceutical companies and middle to small-scale firms are making substantial financial investments in research infrastructure and computational drug discovery workflows to unlock the potential of precision medicines and novel therapeutic compounds.
Furthermore, innovative strides in data processing and analysis are reshaping traditional procedures, particularly in tackling rare diseases like cancer. Next-generation sequencing, coupled with advancements in healthcare IT and pharma nanotechnology sectors, holds promise in diverse areas such as pregnancy, lactation, and combating the SARS-CoV-2 virus. Data-driven software empowers preclinical research, accelerating discoveries in healthcare and beyond. Pharma firms are leveraging both public data and internal datasets, integrating them for enhanced insights through machine learning algorithms. This synergy aids in advancing drug therapeutics, particularly in genomics and molecular simulation, driving predictive modeling for personalized medicine. Additionally, such technologies optimize drug manufacturing processes and meet the evolving demands for vaccines in healthcare
Market Scope |
|
Report Coverage |
Details |
Page number |
167 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 18.17% |
Market growth 2024-2028 |
USD 7.28 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
15.63 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 29% |
Key countries |
US, Germany, UK, China, and France |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Aragen Life Sciences Pvt. Ltd., Certara Inc., Charles River Laboratories International Inc., ChemAxon Ltd., ChemBridge Corp., Collaborative Drug Discovery Inc., Cresset BioMolecular Discovery Ltd., Curia Global Inc., Dassault Systemes SE, Eurofins Scientific SE, Evotec SE, Infosys Ltd., Insilico Medicine, International Business Machines Corp., Jubilant Pharmova Ltd., Melissa Inc., OpenEye Scientific Software Inc., PerkinElmer Inc., Schrodinger Inc., Selvita SA, and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period. |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Solution
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.